Resources

ImmBio is located on the Babraham Research Campus, home of the Babraham Institute, south west of Cambridge City Centre and close to the world-class Addenbrookes Hospital. The Institute is a unit of the UK’s Biotechnology & Biological Research Council (BBSRC), undertaking research and postgraduate education. The campus also has a thriving biotechnology community as part of the wider biotechnology cluster centred around Cambridge, enabling considerable cross-fertilization of ideas, capabilities and facilities.

ImmBio is governed by a Board of Directors, comprising of an independent chairman, two directors drawn from investors and an independent director (all of whom are non-Executive) plus the CEO.

The Executive comprises the Founder & CSO, the CEO and the Development Director.

ImmBio runs its own labs in two key areas – cell & bacterial culture and protein chemistry. It also has access to a number of local facilities, such as those at the Babraham Institute and the mass spectroscopy at the University of Cambridge. However, the majority of the activities are outsourced. ImmBio employs professional project managers, to direct and integrate the multiple activities required for successful product development.

In addition to product development, to better understand the science underpinning the technology and undertake research which will feed through to further breakthrough products, collaborations with leading research centres are in place. These include:

• The Department of Pathology, Cambridge University
• The School of Microbiological Sciences, University of Reading
• The National Institute for Biological Standards & Control (NIBSC)
• The Department of Cellular & Molecular Medicine, University of Bristol
• Centre for Gastroenterology in the Institute of Cell and Molecular Science (ICMS) at Barts and The London, Queen Mary's School of Medicine and Dentistry
• University of Nottingham, Institute of Infection, Immunity and Inflammation
• University College London (UCL), Department of Biochemical Engineering
• University of Surrey, Microbial Sciences

ImmBio also has a number of expert technical consultants to assist in specialised areas such as regulatory, biomanufacturing, patents and molecular biology. Scientific Boards provide advice on specific programmes.

ImmBio has built an IP portfolio that comprises eleven distinct patent families these. The patents address composition, manufacture and use of vaccines including:

• Microbial HspCs (including bacterial and fungal HspCs)
• Viral HspCs
• Tumour HspCs
• Recombinant HspCs
• Screening and use of HspCs
• Manufacture and use of HspCs
• Fusion constructs

ImmBio also holds trademarks on a number of names related to the company and vaccine products.

Beyond IP, ImmBio has built a significant body of know-how around critical areas, such as product constructs, process design and key assays.